Michael Edward Szperka

Array ( [id] => 19142194 [patent_doc_number] => 20240141019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => OPTIMIZED FACTOR VIII GENE [patent_app_type] => utility [patent_app_number] => 18/461697 [patent_app_country] => US [patent_app_date] => 2023-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34476 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18461697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19032538 [patent_doc_number] => 20240082353 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => METHODS FOR PREVENTING OR TREATING ALLERGY BY ADMINISTERING AN IL-4R ANTAGONIST [patent_app_type] => utility [patent_app_number] => 18/452155 [patent_app_country] => US [patent_app_date] => 2023-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14181 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18452155 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20173035 [patent_doc_number] => 12391768 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-19 [patent_title] => Antibodies to ticagrelor and methods of use [patent_app_type] => utility [patent_app_number] => 18/451751 [patent_app_country] => US [patent_app_date] => 2023-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 29 [patent_no_of_words] => 20794 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18451751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067283 [patent_doc_number] => 20240101709 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => THERAPEUTIC ANTIBODIES THAT BIND TO THE SERINE PROTEASE DOMAIN OF MASP-2 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/450194 [patent_app_country] => US [patent_app_date] => 2023-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33299 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18450194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18808651 [patent_doc_number] => 20230382985 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => C3-BINDING AGENTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/447741 [patent_app_country] => US [patent_app_date] => 2023-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59909 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -114 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18447741 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18754036 [patent_doc_number] => 20230357407 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => BISPECIFIC ANTI PD1-ANTI TIM3 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/359660 [patent_app_country] => US [patent_app_date] => 2023-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22448 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18359660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20033340 [patent_doc_number] => 20250171562 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-29 [patent_title] => DISPLACERS OF IGE-FCERI [patent_app_type] => utility [patent_app_number] => 18/880418 [patent_app_country] => US [patent_app_date] => 2023-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32978 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18880418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19027322 [patent_doc_number] => 11926669 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-12 [patent_title] => Anti-FcRn antibody or antigen binding fragment thereof with improved stability [patent_app_type] => utility [patent_app_number] => 18/340722 [patent_app_country] => US [patent_app_date] => 2023-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 28906 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18340722 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19300028 [patent_doc_number] => 20240228597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => ANTI-RESPIRATORY SYNCYTIAL VIRUS ANTIBODIES, METHODS OF THEIR GENERATION AND USE [patent_app_type] => utility [patent_app_number] => 18/337918 [patent_app_country] => US [patent_app_date] => 2023-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68176 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18337918 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18939620 [patent_doc_number] => 20240034759 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => IMMUNOGENIC PEPTIDES AND THEIR USE IN IMMUNE DISORDERS [patent_app_type] => utility [patent_app_number] => 18/332985 [patent_app_country] => US [patent_app_date] => 2023-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33677 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18332985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18817529 [patent_doc_number] => 20230391869 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => INHIBITION OF PLATELET AGGREGATION USING ANTI-HUMAN GPVI ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/316564 [patent_app_country] => US [patent_app_date] => 2023-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30793 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18316564 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18725865 [patent_doc_number] => 20230340094 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => Tau Immunotherapy [patent_app_type] => utility [patent_app_number] => 18/305109 [patent_app_country] => US [patent_app_date] => 2023-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22594 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18305109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18628284 [patent_doc_number] => 20230287141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => ANTI-COAGULATION FACTOR XI ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/302033 [patent_app_country] => US [patent_app_date] => 2023-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30266 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18302033 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18596073 [patent_doc_number] => 20230270864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS [patent_app_type] => utility [patent_app_number] => 18/134430 [patent_app_country] => US [patent_app_date] => 2023-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42992 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18134430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20343132 [patent_doc_number] => 12466854 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-11 [patent_title] => Peptide useful for the transport of molecules through cell barriers [patent_app_type] => utility [patent_app_number] => 18/850224 [patent_app_country] => US [patent_app_date] => 2023-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 9 [patent_no_of_words] => 0 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18850224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18673087 [patent_doc_number] => 20230310560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => FACTOR IX POLYPEPTIDE FORMULATIONS [patent_app_type] => utility [patent_app_number] => 18/184821 [patent_app_country] => US [patent_app_date] => 2023-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16793 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18184821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18986473 [patent_doc_number] => 20240058442 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => Combinations of Modalities for the Treatment of Diabetes [patent_app_type] => utility [patent_app_number] => 18/183465 [patent_app_country] => US [patent_app_date] => 2023-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14171 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18183465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19638097 [patent_doc_number] => 12168698 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-17 [patent_title] => Tissue factor pathway inhibitor antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 18/182619 [patent_app_country] => US [patent_app_date] => 2023-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 41 [patent_no_of_words] => 59866 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 319 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18182619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19291588 [patent_doc_number] => 12030934 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-09 [patent_title] => Modified immunoglobulins for targeting amyloid deposits [patent_app_type] => utility [patent_app_number] => 18/181489 [patent_app_country] => US [patent_app_date] => 2023-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 33 [patent_no_of_words] => 53215 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 292 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18181489 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18922971 [patent_doc_number] => 20240025975 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PATIENTS WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS [patent_app_type] => utility [patent_app_number] => 18/115226 [patent_app_country] => US [patent_app_date] => 2023-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30862 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18115226 [rel_patent_id] =>[rel_patent_doc_number] =>)